Multivariable analysis using tumor size and CTNNB1 mutation status only identified the presence of a S45F mutation (HR = 4.64 [95% CI 1.38–15.8]) as a predictive factor for the initiation of active treatment (Table 2). The gene discussed is CTNNB1; the disease is neoplasm.